folder

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas

Authors

  • A. Arnold
  • S. Daum
  • M. von Winterfeld
  • E. Berg
  • M. Hummel
  • B. Rau
  • U. Stein
  • C. Treese

Journal

  • Clinical and Translational Oncology

Citation

  • Clin Transl Oncol 22 (12): 2357-2363

Abstract

  • INTRODUCTION: The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction and stomach (AEG/S). METHODS: This study analyzed the prevalence, characteristics and prognostic impact of Claudin 18.2 expression in primary tumor, lymph node and distant metastasis in a large Caucasian AGE/S cohort with 414 patients. RESULTS: Claudin 18.2 was highly expressed in 17.1% of primary tumors, 26.7% of lymph node metastasis and 16.7% of distant metastasis. High Claudin 18.2 expression in lymph node metastasis and primary tumors correlated significantly (p < 0.001). High expression of Claudin 18.2 was neither associated with histomorphogical subtype, or tumor state, nor with overall survival. CONCLUSION: In Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 expression itself has no impact on prognosis and is not related to any tumor subtype.


DOI

doi:10.1007/s12094-020-02380-0